Thomas Bumol Increases Stake in Omeros Corporation

On June 18, 2026, Thomas Bumol purchased 15,000 shares of Omeros Corporation (NasdaqGM: OMER). The transaction did not involve a set purchase price. As of Monday, the stock was trading near $10.28.

Insider Buying and Selling at Omeros Corporation

Several insiders, including Thomas Bumol, acquired 15,000 shares each of Omeros Corporation on June 18, 2026. These transactions were not part of any pre-planned trading scheme. Alongside Bumol, insiders such as Leroy Hood, Diana Perkinson, Rajiv Shah, Arnold Hanish, and Peter Demopulos also made similar purchases.

Other Institutional Activity in Omeros Corporation

Institutional investors have been active in Omeros Corporation. BlackRock, Inc. increased its holdings by 247,188 shares, ending with over 5.3 million shares valued at approximately $56.1 million. Ingalls & Snyder LLC added 110,724 shares, bringing its total to nearly 3.6 million shares worth about $37.6 million. Vanguard Capital Management LLC opened a new position with 2,983,259 shares valued at $31.5 million. UBS Group AG and State Street Corp also adjusted their positions, with State Street boosting its holdings by 22% to nearly 1.9 million shares.

Omeros Corporation Stock Down 44.5%

Shares of Omeros Corporation traded near $10.28 on Monday. The company has a market capitalization of roughly $744 million and a P/E ratio of 9.02. Over the past year, the stock has ranged from $2.95 to $17.65. Its 50-day moving average is $12.22, while the 200-day moving average stands at $10.11. Omeros also maintains a healthy current ratio of 3.03 and a quick ratio of 2.48.

Analysts Set New Price Targets

Analysts have shown interest in Omeros Corporation. On April 21, 2026, D. Boral Capital maintained a 'buy' rating with a $36 price target. HC Wainwright & Co. also maintained a 'buy' rating with a $40 target earlier in the year. The consensus among analysts is a 'buy' recommendation, with a mean price target of $40.

About Omeros Corporation

Omeros Corporation is a Seattle-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It primarily targets immunologic diseases and orphan indications. The company's leading product candidate, Narsoplimab, is in clinical trials for various conditions, including COVID-19 and acute respiratory distress syndrome. Founded in 1994, Omeros is led by CEO Dr. Gregory A. Demopulos and employs around 175 people.

Bottom Line

Thomas Bumol's recent purchase of Omeros Corporation shares reflects ongoing interest in the company's potential. As a clinical-stage biotech firm, Omeros continues to attract attention from institutional investors and analysts alike. It's important to note that insider transactions like Bumol's are reported after the fact and may not indicate future performance.